Verona Drug Patent Portfolio
Verona owns 1 orange book drug protected by 5 US patents Given below is the list of Verona's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12251384 | Particulate composition | 25 Jun, 2044 | Active |
| US12409180 | Formulation Production Process | 20 Feb, 2043 | Active |
| US10945950 | Liquid inhalation formulation comprising RPL554 | 15 Sep, 2035 | Active |
| US9956171 | Liquid inhalation formulation comprising RPL554 | 15 Sep, 2035 | Active |
| US9062047 | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound | 21 Aug, 2031 | Active |
Latest Legal Activities on Verona's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Verona.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 09 Sep, 2025 | US12409180 |
| Patent Issue Date Used in PTA Calculation | 09 Sep, 2025 | US12409180 |
| Mail Patent eGrant Notification | 09 Sep, 2025 | US12409180 |
| Recordation of Patent eGrant | 09 Sep, 2025 | US12409180 |
| Email Notification | 09 Sep, 2025 | US12409180 |
| Email Notification | 28 Aug, 2025 | US12409180 |
| Issue Notification Mailed | 27 Aug, 2025 | US12409180 |
| Information Disclosure Statement (IDS) Filed | 26 Aug, 2025 | US9956171 |
| Information Disclosure Statement (IDS) Filed | 26 Aug, 2025 | US9062047 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US10945950 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US9062047 |
| transaction for FDA Determination of Regulatory Review Period | 26 Aug, 2025 | US9956171 |
| Dispatch to FDC | 18 Aug, 2025 | US12409180 |
| Dispatch to FDC | 15 Aug, 2025 | US12409180 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Aug, 2025 | US9956171 |
Verona's Family Patents
Verona Drug List
Given below is the complete list of Verona's drugs and the patents protecting them.
1. Ohtuvayre
Ohtuvayre is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12251384 | Particulate composition |
25 Jun, 2044
(18 years from now)
| Active |
| US12409180 | Formulation Production Process |
20 Feb, 2043
(16 years from now)
| Active |
| US10945950 | Liquid inhalation formulation comprising RPL554 |
15 Sep, 2035
(9 years from now)
| Active |
| US9956171 | Liquid inhalation formulation comprising RPL554 |
15 Sep, 2035
(9 years from now)
| Active |
| US9062047 | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound |
21 Aug, 2031
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ohtuvayre's drug page